HIV vaccine candidate shows early promise
over 1 year in The Mercury
The vaccine, called eOD-GT8 60mer, had a "favorable safety profile" and induced broadly neutralizing antibodies in 97%, or all but one, of the 36 recipients, according to the researchers from Scripps Research, the Fred Hutchinson Cancer Center, the National Institutes of Health and other institutions in the United States and Sweden.
Who is popular today?
